An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells
Shensi Shen(Inserm), Caroline Robert(Centre National de la Recherche Scientifique)
Cited by 99
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
|JAMA|2016|1.1k
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|2017|480